OncoMatch/Clinical Trials/NCT06972875
Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer
Is NCT06972875 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fezolinetant for prostate ca.
Treatment: Fezolinetant — This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone agonists, gonadotropin-releasing hormone antagonists, leuprolide, degarelix, relugolix) — current
Men who are currently receiving Androgen Deprivation Therapy (ADT) for the treatment of prostate cancer. ADT is defined by a history of orchiectomy, or ongoing usage of gonadotropin-releasing hormone agonists or antagonists (e.g. leuprolide, degarelix, relugolix).
Lab requirements
Kidney function
eGFR ≥ 30 mL/min/1.73 m2 based on MDRD estimate
Liver function
No history of cirrhosis; ALT or AST < 2 X ULN; total bilirubin ≤ ULN
History of cirrhosis Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2 X ULN or total bilirubin > ULN eGFR <30 mL/min/1.73 m2 based on reported MDRD estimate.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Vermont Medical Center · Burlington, Vermont
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify